for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AEterna Zentaris Inc. (USA)

AEZS.OQ

Latest Trade

0.53USD

Change

0.03(+6.96%)

Volume

1,318,574

Today's Range

0.51

 - 

0.55

52 Week Range

0.37

 - 

2.57

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Aeterna Zentaris Announces Continued Expansion Of Intellectual Property Portfolio For Macimorelin

July 31 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS ANNOUNCES CONTINUED EXPANSION OF INTELLECTUAL PROPERTY PORTFOLIO FOR MACIMORELIN WITH ADDITIONAL PATENT APPLICATIONS.AETERNA ZENTARIS - BASED ON POSITIVE RESULTS FROM AEZS-130-P01, CO FILED U.S. PROVISIONAL APPLICATION, PATENT APPLICATION UNDER PERCENT.AETERNA ZENTARIS - BOTH PATENT APPLICATIONS RELATE TO INVENTION OF MACIMORELIN AS A METHOD TO DIAGNOSE GROWTH HORMONE DEFICIENCY IN PEDIATRIC PATIENTS.

Lind Global Macro Fund Reports 9.9% Passive Stake In Aeterna Zentaris Inc As Of July 2

July 7 (Reuters) - Lind Global Macro Fund LP::LIND GLOBAL MACRO FUND LP REPORTS 9.9% PASSIVE STAKE IN AETERNA ZENTARIS INC AS OF JULY 2 - SEC FILING.

Aeterna Files For Offering Of Up To 14.5 Million Units, 14.5 Million Pre-Funded Units

June 30 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS INC FILES FOR OFFERING OF UP TO 14.5 MILLION UNITS AND UP TO 14.5 MILLION PRE-FUNDED UNITS - SEC FILING.

Aeterna Zentaris Announces Distribution Agreement With Megapharm

June 25 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY.AETERNA ZENTARIS INC - MEGAPHARM WILL BE RESPONSIBLE FOR OBTAINING REGISTRATION TO MARKET MACIMORELIN IN ISRAEL AND PALESTINIAN AUTHORITY.AETERNA ZENTARIS INC - REGULATORY PROCESS FOR MACIMORELIN IN ISRAEL IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2021.

Aeterna Zentaris Files Prospectus Related To Disposition Of Up To 6.2 Mln Common Shares - SEC Filing

June 8 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS INC FILES PROSPECTUS RELATES TO THE DISPOSITION FROM TIME TO TIME OF UP TO 6.2 MILLION COMMON SHARES - SEC FILING.AETERNA ZENTARIS INC - CO NOT SELLING ANY COMMON SHARES UNDER THIS PROSPECTUS.

Aeterna Zentaris Reports First Quarter 2020 Financial And Operating Results

May 6 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATING RESULTS.AETERNA ZENTARIS INC - QTRLY REPORTED TOTAL REVENUE $1.1 MILLION VERSUS $0.04 MILLION.AETERNA ZENTARIS INC - QTRLY CONSOLIDATED NET INCOME $0.04 PER SHARE (BASIC).

Aeterna Zentaris Announces Positive Results In Dose-Finding Pediatric Study Of Macimorelin

April 6 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN.AETERNA ZENTARIS-RESULTS GIVE CLINICAL FRAMEWORK TO ADVANCE CO'S PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN AS GROWTH HORMONE DEFICIENCY DIAGNOSTIC.AETERNA ZENTARIS INC - PEDIATRIC PK/PD PROFILE OF MACIMORELIN PROVED TO BE IN EXPECTED RANGE AND GENERALLY COMPARABLE TO DATA IN ADULTS.AETERNA ZENTARIS INC - PLANNED SAFETY AND EFFICACY STUDY P02 EXPECTED TO COMMENCE IN Q4 2020.

Aeterna Zentaris Says Qtrly Loss Per Share $0.05

March 30 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.AETERNA ZENTARIS INC - CLOSELY MONITORING COVID-19 AND ITS IMPACT ON BUSINESS AND OPERATIONS.AETERNA ZENTARIS INC QTRLY LOSS PER SHARE $0.05.

Aeterna Zentaris Reports Qtrly Net Loss Per Share Of $0.02

Nov 7 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS REPORTS THIRD QUARTER 2019 FINANCIAL AND OPERATING RESULTS.AETERNA ZENTARIS INC - QTRLY NET LOSS $0.3 MILLION VERSUS $2.5 MILLION.AETERNA ZENTARIS INC QTRLY NET LOSS PER SHARE $0.02.

Aeterna Zentaris Announces Appointment Of New President And CEO

Oct 4 (Reuters) - Aeterna Zentaris Inc <AEZS.TO>::AETERNA ZENTARIS ANNOUNCES APPOINTMENT OF NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER.AETERNA ZENTARIS INC - APPOINTMENT OF KLAUS PAULINI AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.AETERNA ZENTARIS INC - KLAUS PAULINI REPLACES MICHAEL WARD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up